Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its price objective decreased by analysts at Citigroup from $26.00 to $20.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup‘s target price would suggest a potential upside of 270.37% from the company’s current price.
Other equities research analysts also recently issued reports about the stock. Zacks Research downgraded shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. UBS Group reiterated a “buy” rating on shares of Candel Therapeutics in a research report on Monday, August 17th. HC Wainwright lowered their price target on shares of Candel Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, November 13th. Stifel Nicolaus cut their price objective on shares of Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, November 13th. Finally, Jefferies Financial Group assumed coverage on shares of Candel Therapeutics in a research note on Thursday, October 22nd. They set a “buy” rating and a $25.00 price objective for the company. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $18.29.
View Our Latest Analysis on Candel Therapeutics
Candel Therapeutics Trading Down 7.1%
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. Research analysts anticipate that Candel Therapeutics will post -1.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Candel Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in Candel Therapeutics in the second quarter valued at approximately $51,181,000. Portolan Capital Management LLC lifted its position in Candel Therapeutics by 1.4% during the third quarter. Portolan Capital Management LLC now owns 3,538,561 shares of the company’s stock valued at $36,943,000 after purchasing an additional 48,163 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Candel Therapeutics by 4.1% during the third quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock valued at $3,316,000 after purchasing an additional 12,385 shares during the last quarter. Bank of America Corp DE bought a new stake in Candel Therapeutics during the second quarter valued at approximately $2,873,000. Finally, Wellington Management Group LLP purchased a new position in Candel Therapeutics in the 2nd quarter worth approximately $2,119,000. 13.93% of the stock is currently owned by institutional investors.
Latest Candel Therapeutics News
Investors following CADL have been watching these news items:
- Neutral Sentiment: HC Wainwright maintained its Buy rating and $18 price target, while raising its FY2026 loss estimate. The target is a supportive signal, but the firm’s longer-range forecasts were cut substantially. MarketBeat analyst estimates
- Negative Sentiment: HC Wainwright lowered projected earnings for FY2027 through FY2030, including moving its FY2028 estimate from a profit to a loss. Brookline’s estimates also point to ongoing quarterly losses through 2027, reinforcing concerns about the path to profitability. MarketBeat analyst estimates
- Negative Sentiment: Law firms announced investigations and investor notices following Candel’s delay of its aglatimagene biologics license application (BLA) for prostate cancer to mid-2027. The notices allege potential securities-law issues; they are not findings of wrongdoing. The filing delay had already triggered a sharp selloff, and the legal scrutiny could add uncertainty. SBS Law investigation notice Levi and Korsinsky investigation notice
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Recommended Stories
- Five stocks we like better than Candel Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
